Login to Your Account

Amgen, Immatics in $1B deal to broaden scope of Bite technology

By Cormac Sheridan
Staff Writer

Monday, January 9, 2017

DUBLIN – Immatics Biotechnologies GmbH is getting $30 million up front and could earn more than $1 billion in development, regulatory and commercial milestones from an immuno-oncology alliance with Amgen Inc.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription